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Abstract
Background: The risk of an individual to develop an acute kidney injury (AKI), or its severity, cannot be reliably
predicted by common clinical risk factors. Whether genetic risk factors have an explanatory role poses an
interesting question, however. Thus, we conducted a systematic literature review regarding genetic predisposition
to AKI or outcome of AKI patients.
Methods: We searched Ovid SP (MEDLINE) and EMBASE databases and found 4027 references to AKI. Based on
titles and abstracts, we approved 37 articles for further analysis. Nine were published only as abstracts, leaving 28
original articles in the final analysis. We extracted the first author, year of publication, study design, clinical setting,
number of studied patients, patients with AKI, ethnicity of patients, studied polymorphisms, endpoints, AKI definition,
phenotype, significant findings, and data for quality scoring from each article. We summarized the findings and scored
the quality of articles.
Results: The articles were quite heterogeneous and of moderate quality (mean 6.4 of 10).
Conclusions: Despite different gene polymorphisms with suggested associations with development or severity or
outcome of AKI, definitive conclusions would require replication of associations in independent cohort studies and,
preferably a hypothesis-free study design.
Keywords: Acute kidney injury, Genetic variation, Genetic polymorphism
Background
Approximately 40 % of critically ill patients develop acute
kidney injury (AKI) [1, 2]. Despite other underlying condi-
tions, such as sepsis or circulatory collapse, AKI is inde-
pendently associated with longer hospital stay and
increased mortality [3]. The most recent classification of
AKI, namely the KDIGO (Kidney Disease: Improving
Global Outcomes) [4] still uses serum-creatinine and
urine-output measurements to assess kidney function.
No reliable method exists that is able to predict the in-
dividual risk to develop, or to survive, AKI. Genetic vari-
ability offers an intriguing research focus, since clinical
risk factors explain only part of the conferred risk [5].
Other complex disease states have been investigated for
their genetic etiology with promising results, including
Crohn’s disease and type 2 diabetes [6, 7]. However, the
odds ratios for the common genetic variants known to
associate with such traits have been rather modest, ap-
proximately 1.1 for the heterozygote genotypes [8].
Individual susceptibility to develop AKI and to influence
disease progression have been studied using candidate
gene association studies. The literature has been evaluated
in two systematic reviews. Lu and colleagues [9] searched
articles until the year 2007, and Cardinal-Fernández and
colleagues [10] until 2011. Both concluded that no defini-
tive evidence of association of certain genetic variation
with AKI exists so far.
Accordingly, we sought to update the current litera-
ture about genetic association to AKI with special em-
phasis on the quality of the studies.
Methods
Literature search and selection of studies
We systematically searched the OvidMedline and
Embase databases for relevant articles from the year
2000 until March 5, 2015. The databases were selected
according to the recommendation of The Human
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Genome Epidemiology Network (HuGENet) guidelines
[11]. We conducted the search using strategies optimized
to each database. We aimed to find articles with interest
in genetic variability in acute kidney injury. The search
criteria were: Genes OR genotype OR phenotype OR poly-
morphisms OR allelism OR heredity AND acute kidney
failure OR acute kidney injury OR acute kidney insuffi-
ciency OR acute renal failure OR acute renal injury OR
acute renal insufficiency OR acute nephropathy. We used
appropriate abbreviations and word truncations, as well as
proximity operators, to make the search more compre-
hensive. The multitude of the near-synonymous terms
used in the search is due to the fairly recent acceptance of
‘acute kidney injury’ as the one term to describe the
phenomenon, as well as numerous possible ways to dis-
cuss genetic variability. We conducted the search with the
assistance of a university library information specialist
(Helsinki University Library, Terkko, Finland) in English
language on March 5, 2015. More detailed information
about performing the search is available in Additional ma-
terial (Additional files 1 and 2).
After the removal of duplicates, the search resulted in
4027 references. Articles presenting an original study
about human genetic variability and its possible associ-
ation with AKI were selected for further analysis. We
screened titles and abstracts and categorized the articles
according to the predefined inclusion and exclusion cri-
teria. Exclusion criteria were determined in an attempt
to explore the most common contributors to AKI in
adult subjects in a hospital setting. Exclusion was either
because of the studied subjects (pediatric patients, organ
transplantation patients, experimental animals) or
methods used (case studies, review articles). In addition,
a number of articles were excluded because they did not
study AKI or genetic variability in association with AKI,
but focused on chronic renal failure, diabetes, polycystic
kidney disease, thrombotic thrombosytopenic purpura,
haemolytic uremic syndrome, systemic lupus erythema-
tosus, liver failure, predictive biomarkers, glomerulone-
phritides, viral infection, malignancies, or hereditary
syndromes affecting kidneys. The process of article se-
lection is presented in Fig. 1.
Fig. 1 Study flow chart. The literature search was performed on March 5th 2015. Abbreviations: AKI, Acute Kidney Injury
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Two authors (L.V and M.K) independently reviewed 39
articles. Of the 39, 9 were published only as conference
abstracts [12–20], and two were reviews. One article was
about racial difference regarding AKI susceptibility, but
failed to explore AKI genetics [21]. We identified one add-
itional article when going through the references of the in-
cluded articles [22], found it relevant and to fulfil our
search criteria and included it according to the HuGENet
guidelines [11]. In total, 28 original articles were accepted
into the final analysis.
Data extraction and quality assessment
We extracted the following data from each article: The
first author, year of publication, study design, clinical set-
ting, number of all genotyped subjects, number of pa-
tients, number of patients with AKI, ethnicity, studied
polymorphisms, endpoints, definition of AKI, intermedi-
ate phenotype, and significant findings. In addition, we
assessed the study quality according to the scoring by
Clark et al. [23]. We graded each study on a binary scale
of ten quality criteria. One point for each criterion leads
to the maximum points of ten. The criteria were prede-
termined and adapted for better evaluation (Table 1).
Studies that were published solely as abstracts [12–17]
were not included in this scoring, however some data
were extracted and are presented in Additional material
(Additional file 3). All correlation calculations were per-
formed using SPSS Statistics version 22 (IBM Corp.,
Armonk, NY, USA).
Results
Characteristics of articles
The 28 articles in the final analysis were published be-
tween 2000 and 2014. The characteristics of the articles
are described in detail in Table 2.
The number of the patients studied varied between 61
and 1741 (median 262) with a total of 12272. The num-
ber of patients with AKI was between 2 and 459 (median
115), but not stated in three studies [24–26]. In six stud-
ies [22, 27–31] all genotyped subjects had AKI, in
addition to a cohort within one study [32], which com-
prised only AKI patients. The reviewed articles were
grouped into those studying AKI susceptibility and those
studying AKI-related outcome. The data extracted from
the reviewed articles are presented as Additional file 4
for AKI susceptibility studies and Additional file 5 for
AKI related outcome studies.
Table 1 Study quality scoring system adapted from Clark et al. [23]. Studies were assessed using specific criteria described below
and scored 1 point if a criterion was fulfilled. [Adaptation by current reviewers in italic]
Criterion Original criteria by Clark et al. Specific criteria
1. Defining the Control
Group
Control group described for size in relation to case group
(n > case group) and ethnicity, in sufficient detail to allow
replication. Cohort studies do not get a point.
Cohort studies are given a point provided that the cohort is
described in sufficient detail, namely the ethnicity of a cohort
is given. Prospective cohorts regarded as strong design in
demonstrating causality between genetic polymorphism and
the development of acute kidney injury (AKI). a Size of the
control group sufficient when essentially equivalent with case
group.
2. Hardy-Weinberg
Equilibrium
Case and control groups assessed for Hardy-Weinberg
equilibrium (HWE).
Cohort or control group should be in HWE (p > 0.01). In case
of multiple polymorphisms, the majority should be in HWE.
3. Defining the Case
Group
The disease state of interest as well as inclusion and
exclusion criteria of the case group defined in sufficient
detail to allow replication.
Studies that aim to investigate predisposition to AKI are given
a point only if they describe the phenotype.
4. Primer Sequence The priming sequences used for genotyping or
references to them provided.
Whenever a commercial assay was used for genotyping, a point
was given as well.
5. Describing the Methods Genotyping method described in sufficient detail to
allow replication. In addition, second validating assay
performed or the accuracy of the assay validated.
Accepted quality control methods: duplicated samples or control
samples included, second independent investigator analyzing
the genotype calls, repeating of ambiguous results.
6. Blinding Genotyping performed blinded to clinical status.
7. Power Calculation Prospective or retrospective power calculation
performed.
No retrospective power calculations were conducted by the
reviewers.
8. Statistics Tests of significance presented: such as p values,
confidence intervals, or odds ratios.
9. Corrected Statistics Corrected for the increased risk of false-positive error
in the case of multiple polymorphisms studied. Should
X2 or odds ratio be used, Hardy-Weinberg equilibrium
is to be assessed.
Where there was only one polymorphism studied, a point was
given.
10. Replication Study performing second, confirmatory study or
confirming earlier polymorphism study.
A point was given only for studies performing exact replication
of a polymorphism in association with a phenotype.
aIn accordance with Lu et al. [9]
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Quality of the articles
The mean quality score was 6.4 (range 3–10). (Please see
additional file 6). All the studies fulfilled the requirement
of reporting basic statistical significance. The AKI
phenotype, along with inclusion and exclusion criteria,
was adequately defined in 25/28 (89 %) studies. All but
two (N = 26, 93 %) of the studies provided adequate
information about the primer sequences of the genotyp-
ing assay.
Only six of 28 (21 %) of the studies reported power
calculations [24, 33–37] and only two disclosed the odds
ratios [34, 35]. In addition, two of these six studies had
some other primary end point than the development or
outcome of AKI [24, 35]. Ten of the studies [25, 30, 35–42]
could be regarded as replication attempts, since they in-
cluded at least one polymorphism previously reported to be
associated with AKI or related traits. Furthermore, in two
(7 %) of the studies [32, 34] showing evidence of associ-
ation, the result was confirmed in an independent patient
sample.
The correlation between the two reviewers before con-
sensus was good (Spearman’s rho coefficient 0.90). The
mean score for each of the ten quality criteria is pre-
sented in Fig. 2.
Of the 28 studies in our review, six (21 %) [24, 25, 27,
28, 38, 43] had been scored previously by Lu [9] (scored
6.0 in this study [range 4–8] vs. Lu et al. 6.3 [range 4–8]),
(Spearman’s rho coefficient 0.81).
Genes associated with AKI
The main results are presented in Fig. 3, which lists the
investigated genes. Colour coding shows whether the re-
sult has been positive or negative and whether the asso-
ciation was found with susceptibility to AKI or its
outcome. For more information about the studied poly-
morphisms and the negative findings, please see
Additional files 4 and 5.
Inflammatory genes
Jouan et al. [44] could not confirm any association be-
tween interleukin 6 (IL-6) gene −572 G/C polymorphism
(rs1800796) or interleukin 10 (IL-10) gene −592 C/A
polymorphism (rs1800872) and acute renal insufficiency.
Stafford-Smith et al. [25] found that a combination of
angiotensinogen (AGT) gene +842C –allele (rs699) and
IL-6–572C –allele in Caucasians is associated with renal
dysfunction.
The high-producer genotype AA + GA of tumor necro-
sis factor alpha (TNFA) gene −308 G/A polymorphism
(rs1800629) was found by Jaber et al. to be associated
with higher levels of TNF-α ex vivo and higher mortal-
ity in patients receiving renal replacement therapy
(RRT) [27]. They also demonstrated that IL-10 poly-
morphism −1082 G/A intermediate/high producer
(GA + GG) genotype (rs1800896) was associated with
higher levels of IL-10 and lower mortality in the same
patient group [27]. Chang et al. [45] found that in pa-
tients undergoing percutaneous coronary intervention
(PCI), the A-allele of TNFA gene −308 polymorphism,
as well as the G-allele of IL-10–1082 polymorphism
were more prevalent among patients with contrast-
Table 2 Characteristics of articles
Characteristic N References
Clinical setting
Post cardiac surgery 12 [24, 25, 36–39, 42–44, 46–48]
ICU treatment 6 [26, 33, 34, 40, 41, 49]
Hospitalization with
kidney injury
5 [22, 28–31]
Dialysis 1 [27]
Other 4 [32, 35, 45, 50]
Study design
Prospective cohort 23 [22, 24–30, 32, 33, 36–40, 42–44, 46–50]
Prospective case–control 4 [31, 35, 41, 45]
Retrospective case-
cohort
1 [34]
Center of data acquisition
Single 14 [25, 26, 33, 36, 37, 40, 41, 43–48, 50]
Multi 12 [22, 27–32, 34, 35, 39, 42, 49]
Not applicable 2 [24, 38]
Definition of AKI
RIFLE 8 [33, 36–40, 42, 46]
AKIN 7 [22, 30–32, 34, 41, 49]
Renal-SOFA 1 [26]
Administration of RRT 2 [44, 47]
Creatinine level 4 [28, 29, 35, 45]
Not applicable 6 [24, 25, 27, 43, 48, 50]
Studied polymorphisms
1 polymorphism 11 [24, 29, 30, 33, 37, 39, 43, 46–49]
1 gene, several
polymorphisms
4 [22, 26, 31, 32]
Several genes 12 [25, 27, 28, 35, 36, 38, 40–42, 44, 45, 50]
GWAS 1 [34]
Ethnicity
Caucasian 9 [31, 33–36, 40, 46–48]
Mixed 10 [22, 24, 25, 27–30, 32, 49, 50]
Not applicable 9 [26, 37–39, 41–45]
Main outcome
AKI 26 [22, 25–34, 36–50]
Other 2 [24, 35]
Abbreviations: AKI Acute Kidney Injury, AKIN Acute Kidney Injury Network
-classification, GWAS Genome-Wide Association Study, ICU Intensive Care Unit,
RIFLE Risk Injury Failure Loss of function End stage -classification, RRT renal
replacement therapy, SOFA, Sequential Organ Failure Assessment score
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induced acute kidney injury. Furthermore, the low-
producing genotypes of the aforementioned polymor-
phisms were associated with the risk of AKI, as were
the haplotypes T-C-A of TNFA and C-A-C-G of IL-10.
Dalboni et al. [41] showed that the GG genotype of
TNFA −308 polymorphism and AA genotype of IL-10–
1082 polymorphism, when combined, are associated
with AKI and/or death, and also with RRT and/or death.
Susantitaphong et al. [30] found that TNFA gene −308 G/
A A-allele was associated with higher peak serum creatin-
ine and urinary kidney injury molecule-1 (KIM-1), as well
as higher multi organ failure (MOF) score in hospitalized
patients with AKI. The TNFA gene was the most investi-
gated, with both positive and negative results (Fig. 3).
In a study by Sole-Violan et al. [35], an association
was found between homozygosity for receptor IIa of the
Fc portion of immunoglobulin G (FCGR2A-H131) allele
in the rs1801274 polymorphism and development of
acute renal failure in patients with pneumococcal
community-associated pneumonia.
Vasomotor regulation genes
Six studies investigated angiotensin converting enzyme
(ACE) insertion/deletion (I/D) polymorphism (rs4646994)
[25, 26, 33, 38, 40, 42]. Isbir et al. [38] were able to find a
significant association between ACE D–allele and an in-
creased risk of postoperative AKI after coronary artery by-
pass grafting (CABG). Contradictory to this, du Cheyron
et al. [33] found that I/I genotype is associated with an in-
creased risk for AKI and administration of RRT. The
remaining studies failed to detect association either in the
intensive care unit [26, 40] or after cardiac surgery [25, 42].
Haase-Fielitz [46] studied a low activity (L) Val158Met
polymorphism (rs4680) within the catechol-O-methyl-
transferase (COMT) gene. The low-activity genotype
(LL) was associated with AKI and more frequent adminis-
tration of furosemide and RRT. However, results by Albert
et al. [39] and Kornek et al. [37] suggest no association
between this COMT polymorphism and AKI. Association
between the C-allele of the endothelial NO synthase
(eNOS) -786 T/C polymorphism (rs2070744), low creatin-
ine clearance, and more frequent administration of RRT
has also been reported [47]. Alam et al. [31] found that
phenylethanolamine N-methyltransferase (PNMT) gene
rs5638 + 1543 G –allele is associated with an increased
risk for AKI, and the genotype +1543 G/A is associated
with oliguria, whereas PNMT rs876493 -161 A –allele is
associated with lower mortality and less circulatory shock.
Other genes
The non-e4-allele of polymorphisms rs429358 and
rs7412 of apolipoprotein E (APOE) have appeared to as-
sociate with a higher maximum creatinine [24, 43], and
with increased risk of postoperative AKI [38], in two
studies unable to find any association in this post-CABG
setting [36, 44]. A study by Kolyada [29] showed that the
T-allele of an rs11549465 polymorphism +85 C/T on
transcription factor hypoxia-inducible factor-1alpha
(HIF-1α) gene is associated with higher use of dialysis.
In 2007, Perianayagam and colleagues found a +242
C/T polymorphism (rs4673) in the pro-oxidant enzyme
NADPH (Nicotinamide Adenosine Dinucleotide Phos-
phate) oxidase p22phox gene T-allele, associated with
more prolonged length of hospital stay, higher dialysis
use, and higher odds for composite outcome [28].
In 2012, Perianayagam et al. [32] found an association
in a primary cohort of AKI patients between the myelo-
peroxidase (MPO) gene −765 T/C (rs2243828), +9890
A/C (rs2071409), and +2149 T/C (rs2759) polymor-
phisms and lower urine output as well as the composite
outcome of dialysis administration or in-hospital death,
and with MPO +157 G/T polymorphism (rs7208693)
and more advanced AKI as well as the aforementioned
composite outcome.
Cytochrome b245, α subunit (CYBA) gene, was investi-
gated in a study by Perianayagam et al. [22] who found
Fig. 2 Quality scores according to each criterion. (Full description of criteria is given in Table 1)
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Fig. 3 (See legend on next page.)
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that rs8854 A-allele was associated with less dialysis re-
quirement or in-hospital death compared with the GG
genotype. The haplotype A-A-G-G of polymorphisms
rs4782390, rs4673, rs3794624, and rs8854 associated
with an increased risk of this outcome.
Popov found the erythropoietin (EPO) gene rs1617640
T/G -polymorphism TT-genotype to be associated with
increased creatine phosphokinase-MB (CPK-MB) and
administration of RRT, but no association with AKI was
found [48].
Payen and colleagues [49] found an association be-
tween the presence of 4 human leukocyte antigen-DR-
beta (HLA-DRB) alleles and less administration of RRT,
but not with development of AKI.
In a study by Henao-Martínez et al., [50] the poly-
morphisms rs10786691, rs12414407, rs10748825, and
rs7078511 in the suppressor of fused homolog (SUFU)
gene, correlated with renal function in hospitalized pa-
tients with Enterobacteriacea sepsis. Vascular endothe-
lial growth factor (VEGF) gene polymorphism +936
(rs3025039) CC-genotype was found associated with
AKI by Cardinal-Fernández [40].
Associations identified by a hypothesis-free study design
In a study by Frank [34], two polymorphisms (rs8094315
and rs12457893) within a B-cell CLL/lymphoma 2
(BCL2) gene and a single polymorphism (rs2093266) in
a serpin peptidase inhibitor, clade A (alpha-1 antiprotei-
nase, antitrypsin) member 4 (SERPINA4) gene were found
to protect from AKI, and a polymorphism (rs625145) in
salt-inducible kinase 3 (SIK3) gene was found to be associ-
ated with increased risk for AKI.
Polymorphisms studied for their association with the
development of AKI and published only as abstracts are
summarized in Additional file 3.
Discussion
In this systematic review we identified 28 studies exam-
ining genetic predisposition to the development and/or
outcome of AKI. Based on a previously-published
quality-scoring method utilized and further developed in
this review, these few identified studies had inadequate
quality (mean score 6.4/10). The studies were heteroge-
neous in defining concepts and outcomes, replicated
with ambiguous results, and underpowered. All but one
of the reviewed studies used a candidate gene approach.
Typically, associations found with such an approach
have been difficult to replicate and the coverage of gen-
etic variation has been poor [51]. Regardless of some re-
ported positive associations [22, 24, 25, 27–35, 38, 40,
41, 44–50], no conclusive data on predisposing genetic
variants exist.
Some generalizations may be made based on the study
designs, however. First, the balance between pro- and
anti-inflammatory mediators was among the most inves-
tigated. Polymorphism rs1800629 in the TNFA gene is
suspected to alter the inflammatory response and to be
associated with AKI susceptibility [41, 45], as well as
outcome [27, 30, 41]. This finding is controversial, how-
ever; in five studies [25, 36, 40, 42, 44] no evidence sup-
ported an association between TNFA and susceptibility or
outcome of AKI. Second, polymorphisms rs429358 and
rs7412 in the APOE–gene have been investigated among
patients undergoing cardiac surgery. Apolipoprotein E is a
protein that is known to function in lipid metabolism but
has other roles as well. The APOE-e4–allele is suggested
to be protective against AKI [24, 38, 43], as is the case
with chronic kidney disease [52]. The inverse is true for
atherosclerosis and Alzheimer’s disease [53, 54]. Third,
renal hemodynamics was one common phenotype of
interest in the studies. Consequently, ACE, providing
a key enzyme in the renin-angiotensin-aldosterone–
pathway, with an effect on renal blood flow, is a
relevant candidate gene and has been investigated in
several studies [25, 26, 33, 38, 40, 42]. Unfortunately,
the described associations in the two studies were in
opposite directions [33, 38] and the other studies
[25, 26, 40, 42] could not confirm any association.
(See figure on previous page.)
Fig. 3 Genes studied for association with either susceptibility to AKI (S) or AKI outcome (O). Red color indicates positive association signals (based
on the interpretation of the authors themselves), where dark red signals higher (≥8) quality score and light red signals lower quality score (3–7).
Blue color indicates no association. Articles are presented alphabetically by the fist author and genes are presented in alphabetical order.
Abbreviations: ACE, Angiotensin Converting Enzyme gene; AGTR1, Angiotensin II Receptor, Type 1 gene; AGT, Angiotensinogen gene; APOE,
Apolipoprotein-E gene; BCL-2, B-cell CLL/lymphoma 2 gene; COMT, Catechol-O-methyltransferase gene; CYBA, Cytochrome b245, α subunit gene;
eNOS, endothelial Nitric Oxide Synthase gene; EPO, Erythropoietin gene; FCGR2A, Receptor IIa of the Fc portion of immunoglobulin G gene;
FCGR3A, Receptor IIIa of the Fc portion of immunoglobulin G gene; FCGR3B, Receptor IIIb of the Fc portion of immunoglobulin G gene; GLI1, Gli
family zinc finger 1 gene; HHIP, Hedgehog Interacting Protein gene; HIF-1-alpha, Hypoxia-Inducible Factor 1-alpha gene; HLA-DRB1, Human
Leukocyte Antigen – Major Histocompatibility Complex, Class II, DR beta 1 gene; IL-6, Interleukin-6 gene; IL-8, Interleukin-8; IL-10, Interleukin-10
gene; LTA, Lymphotoxin Alpha gene; MPO, Myeloperoxidase gene; NADPH, Nicotinamide Adenosine Dinucleotide Phosphate gene; PBEF, Pre-B cell
colony-enhancing factor gene; PNMT, Phenylethanolamine N-methyltransferase gene; PTCH1, Patched homolog 1 gene; PTCH2, Patched homolog
2 gene; SERPINA4, Serpin Peptidase Inhibitor, Clade A (alpha-1 antiproteinase, antitrypsin) Member 4 gene; SERPINA5, Serpin Peptidase Inhibitor,
Clade A (alpha-1 antiproteinase, antitrypsin) Member 5 gene; SIK3, Salt-Inducible Kinase 3 gene; SMO, Smoothened gene; SUFU, Suppressor of
Fused homolog gene; TGF-β, Transient Growth Factor beta gene; TNFA, Tumor Necrosis Factor alpha gene; VEGF, Vascular Endothelial Growth
Factor gene
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Within the assessed studies, the best-fulfilled quality
criteria were: reporting statistics, reporting primer se-
quence, and defining the case group (Fig. 2). Study sta-
tistics were considered adequate if either p-value,
confidence intervals, or odds ratios were mentioned. It
could be argued that at least the p-value and confidence
interval should both be reported in order to correctly
evaluate significance of an association. The quality cri-
teria that were most rarely fulfilled were power calcula-
tion results, replication, method description, and
blinding of clinical status.
Although the initial consensus between the two re-
viewers was good in this study, the reviewers had several
discussions about the specific quality criteria during the
process. In general, the original criteria in the reviewed
studies were rather subjective and, thus, hard to inter-
pret. Furthermore, the drawback of using the criteria by
Clark and colleagues [23] was that these criteria are not
perfectly suited for modern genetic study-design or
high-throughput genotyping methods. Based on these
criteria, points are given relatively easily. More recently,
the high probability of spurious, false-positive associ-
ation signals due to small sample sizes has been better
recognized. Thus, we suggest that when assessing the
quality of a genetic association study, the most important
factors to consider are the sample size and internal repli-
cation. Additionally, if the aim is to study the association
between a certain gene and a disease/dysfunction, it is
crucial that the whole gene should be covered instead of
genotyping some random SNPs (Single Nucleotide
Polymorphism).
The study by Frank and colleagues [34] avoided most
of the weaknesses of the previous studies. Theirs was the
first AKI study to employ large-scale genotyping. The
quality of this work was superior in many regards com-
pared to other studies discussed in this systematic litera-
ture review. They also used an internal replication
approach and divided the patients randomly into discov-
ery and validation cohorts. However, their study design
was not truly hypothesis-free since a large proportion of
the genome was not covered by the genotyping chip
used. Of the 142 SNPs showing evidence of association
in the discovery cohort, only five could be replicated in
the validation cohort. These SNPs were located within
the BCL2, SIK3, and SERPINA4-SERPINA5 genes, sug-
gesting that apoptotic pathways might have a role in de-
termining the susceptibility to AKI.
The inferences based on this review are subject to
some limitations. First, the literature search was con-
ducted in the English language. However, the databases
used were selected on the basis of HuGENet guidelines,
with assistance from an information specialist. Second,
no unpublished data was included in the search. Third,
all the possible genetic analyses made by the researchers
may not have been published in the articles and, thus,
may have led to reporting or publication bias. This may
also influence the understanding of the relationship be-
tween positive and negative results. Fourth, data proved
to be inadequate to allow any meta-analysis. Thus, our
findings are limited to the assessment of the quality and
description of the individual studies. However, 22 (79 %)
and 16 (57 %) of the 28 studies in this review were not
included in the two respective previous reviews [9, 10],
an obvious strength supporting the additional value of
our report.
Conclusions
In this systematic review we found 28 genetic studies fo-
cusing on association with development and/or severity of
AKI. Of note, the majority of these studies lacked ad-
equate quality. Conclusive evidence would still require a
standard definition of AKI, unbiased outcome measures
and replication of associations in a large independent sam-
ple and, preferably, applying a genome-wide hypothesis-
free study design in future research. This systematic re-
view was reported according to the principles in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement (Additional file 7) [55].
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